

REDUCER I

OBSERVATIONAL STUDY

CORONARY SINUS REDUCER FOR TREATMENT OF REFRACTORY ANGINA IN PATIENTS WITH DIABETES MELLITUS¹


REDUCER I is a prospective, open-label, multi-center, international, post-market study which collects long-term data of patients with refractory angina treated with the Shockwave™ Reducer.

DIABETES MELLITUS SUB-ANALYSIS RESULTS

REDUCER I patients with Diabetes Mellitus (DM) showed similar improvement in angina reduction (change in Canadian Cardiovascular Society Class (CCS)), similar Quality of Life (QoL) improvements and no difference in MACE-free survival at 12 months than the patients without history of DM.


Seattle Angina Questionnaire

Patients with and without diabetes showed similar QoL improvements in the mean SAQ summary score at 12 months ($p=0.27$)




Canadian Cardiovascular Society Class

Patients with (71% improvement by ≥ 1 CCS class) and without DM (68% improvement by ≥ 1 CCS class) showed similar improvement in CCS class ($p=0.66$).



Major Adverse Cardiovascular Events

No difference in MACE-free survival between subjects with and without history of diabetes.



KEY TAKEAWAYS FROM THE REDUCER I DIABETES MELLITUS DATA


- Patients with coronary artery disease and DM may have a greater burden of angina than those without DM^{2,3}
- A previous early report suggests that the Shockwave Reducer is equally effective in improving angina symptoms in patients with DM and without DM⁴
- Reducer implantation was safe and as effective for improving angina and QoL in patients with DM compared to those without DM
- These data highlight the potential utility of the Reducer to alleviate angina in patients with DM

CREATING BETTER OUTCOMES WITH MOUNTING
CLINICAL EVIDENCE

REDUCER I
OBSERVATIONAL STUDY

COSIRA II

Scan to Learn More



This is a hypothesis-generating sub-analysis of the Reducer I registry. The registry is limited in its documentation of ischaemia testing and baseline medications.

FOOTNOTES

1. de Silva, R. Results from the REDUCER-I Study. ESC 2025; 2. Peterson P.N. et al. BMC Cardiovasc Disord 2006; 6: 41; 3. Morrow D.A. et al. Circulation 2009; 119: 2032; 4. Vescovo GM et al. Heart Vessels. 2022 Feb;37(2):194-199.

CAUTION In the United States, Shockwave Reducer is an investigational device, limited by United States law to investigational use. The Reducer is subject of Investigational testing and is being studied in the COSIRA-II trial in Canada. The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability. Prior to use, please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events: ifu.sw-reducer.com

© 2025 Shockwave Medical Inc. All rights reserved. SPL-77433 Rev A.

SHOCKWAVE
REDUCER